Interpretation of Chinese guideline for diagnosis and treatment of adult acute lymphoblastic leukemia(2024)
-
摘要: 成人急性淋巴细胞白血病(acute lymphoblastic leukemia，ALL)是成人最常见的急性白血病之一，随着诊断技术和治疗手段快速发展，成人ALL的精准诊断不断更新、临床实践日益丰富。为促进成人ALL临床诊疗的规范，中国抗癌协会血液肿瘤专业委员会、中华医学会血液学分会白血病淋巴瘤学组参考国内外最新指南和文献，荟萃国内外最新研究成果，共同制定了《中国成人急性淋巴细胞白血病诊断与治疗指南(2024年版)》。为更好地指导临床实践，文章拟对该指南重点更新的部分进行解读。Abstract: Adult acute lymphoblastic leukemia(ALL) is one of the most common acute leukemia in adults. With the rapid development of diagnostic technology and novel treatment methods, the precise diagnosis of adult ALL is constantly updated, and clinical practice is increasingly enriched.To promote the standardization of clinical diagnosis and treatment of adult ALL, the Hematology Oncology Committee of the Chinese Anti-Cancer Association and Leukemia & Lymphoma Group of the Chinese Society of Hematology, Chinese Medical Association, have referred to the latest guidelines and literature both domestically and internationally, and have compiled the latest research findings from around the world to jointly formulate the "Chinese guideline for diagnosis and treatment of adult acute lymphoblastic leukemia (2024)"To better guide clinical practice, this article intends to interpret the updated parts of the guideline.
-
Key words:
- acute lymphoblastic leukemia /
- adult /
- diagnosis /
- treatment /
- efficacy monitoring
-
-
[1] 中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会白血病淋巴瘤学组. 中国成人急性淋巴细胞白血病诊断与治疗指南(2016年版)[J]. 中华血液学杂志, 2016, 37(10): 837-845. doi: 10.3760/cma.j.issn.0253-2727.2016.10.002
[2] Panagopoulos I, Micci F, Thorsen J, et al. A novel TCF3-HLF fusion transcript in acute lymphoblastic leukemia with a t(17;19)(q22;p13)[J]. Cancer Genet, 2012, 205(12): 669-672. doi: 10.1016/j.cancergen.2012.10.004
[3] Fischer U, Forster M, Rinaldi A, et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options[J]. Nat Genet, 2015, 47(9): 1020-1029. doi: 10.1038/ng.3362
[4] Lilljebjörn H, Henningsson R, Hyrenius-Wittsten A, et al. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia[J]. Nat Commun, 2016, 7: 11790. doi: 10.1038/ncomms11790
[5] Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403[J]. Blood, 2019, 133(14): 1548-1559. doi: 10.1182/blood-2018-10-881961
[6] DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia[J]. Leukemia, 2015, 29(3): 526-534. doi: 10.1038/leu.2014.229
[7] Gong XY, Fang QY, Gu RX, et al. Pediatric-inspired regimen for adolescent and adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a prospective study from China[J]. Haematologica, 2024, Jan 18. doi:
10.3324/haematol.2023.284228.Epubaheadofprint .[8] Wang Z, Fan Z, Wu Z, et al. PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation[J]. Br J Haematol, 2024, 204(2): 628-637. doi: 10.1111/bjh.19223
[9] Qi HZ, Xu J, Yang QQ, et al. Effect of pediatric-versus adult-type chemotherapy regimens on outcomes of allogeneic hematopoietic stem cell transplants for adult T-cell acute lymphoblastic leukemia in first complete remission[J]. Bone Marrow Transplant, 2022, 57(11): 1704-1711. doi: 10.1038/s41409-022-01796-2
[10] Litzow Mark R, Sun ZX, Elisabeth P, et al. Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN E1910 randomized phase Ⅲ national cooperative clinical trials network trial[J]. Blood, 2022, 140(S2): LBA-1.
[11] Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study[J]. Lancet Oncol, 2018, 19(2): 240-248. doi: 10.1016/S1470-2045(18)30011-1
[12] Jabbour E, Sasaki K, Short NJ, et al. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia[J]. Cancer, 2021, 127(12): 2025-2038. doi: 10.1002/cncr.33469
[13] Jabbour E, Short NJ, Senapati J, et al. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial[J]. Lancet Haematol, 2023, 10(6): e433-e444. doi: 10.1016/S2352-3026(23)00073-X
[14] Foà R, Bassan R, Vitale A, et al. Dasatinib-blinatumomab for ph-positive acute lymphoblastic leukemia in adults[J]. N Engl J Med, 2020, 383(17): 1613-1623. doi: 10.1056/NEJMoa2016272
[15] Wang Y, Wei XD, Yan DM, et al. Sustained Remission and Decreased Severity of CAR-T Cell Related Adverse Events: A Pivotal Study of CNCT19(inaticabtagene autoleucel)Treatment in Adult Patients with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia(R/R B-Cell ALL)in China[J]. Blood, 2022, 140(Supplement 1): 1598-1600. doi: 10.1182/blood-2022-165002
[16] Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia[J]. N Engl J Med, 2016, 375(8): 740-753. doi: 10.1056/NEJMoa1509277
[17] Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia[J]. N Engl J Med, 2017, 376(9): 836-847. doi: 10.1056/NEJMoa1609783
-
计量
- 文章访问数: 624
- 施引文献: 0
下载: